<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82397">
  <stage>Registered</stage>
  <submitdate>7/11/2007</submitdate>
  <approvaldate>9/11/2007</approvaldate>
  <actrnumber>ACTRN12607000575437</actrnumber>
  <trial_identification>
    <studytitle>Fellow Eye Effect with Ranibizumab for Age Related Macular Degeneration</studytitle>
    <scientifictitle>In patients with wet Age Related Macular Degeneration, is ranibizumab intravitreal injection effective in improving visual acuity in the fellow eye?</scientifictitle>
    <utrn />
    <trialacronym>FERMAD</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Age Related Macular Degeneration (wet type, characterised by choroidal neovascularisation)</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observation post-injection by Visual Acuity (VA) measurement and Optical Coherence Tomography (OCT). Patients will be observed on 6 occassions over 3 months from their initial treatment. Visual Acuity will be tested using a standard logMAR eye chart, and retinal OCT will be performed using a Copernicus Spectral OCT scanner.</interventions>
    <comparator>This trial is uncontrolled, due to ethical concerns in witholding vision preserving treatment.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improvement in Visual Acuity, as measured by a gain in letters on logMAR chart. 5 letters will be considered clinically significant.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reduction in macular thickness, as measured by OCT.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in volume of sub-retinal fluid, measured with OCT.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in Visual Acuity of treated eye.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction of macular thickness in treated eye.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction of macular thickness in treated eye.</outcome>
      <timepoint>1day, 3 days, 1 week, 2 weeks, 1 month, 3 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> ARMD with choroidal neovascularisation in both eyes
 Involvement of the foveal centre
 Age 50 years or more
 Visual Acuity (best corrected) of 6/12 or worse in both eyes (equivalent to &gt;0.3 logMAR)</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria> Lesion size greater than 12 optic disc areas
 Previous anti Vascular Endothelial Growth Factor (anti-VEGF) therapy
 Contraindication for ranibizumab treatment
o	Hypersensitivity to ranibizumab
o	Active or suspected ocular/periocular infection
o	Active intraocular inflammation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>18/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3550</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Monash University
Victoria 3800</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Bendigo Health Care Group</sponsorname>
      <sponsoraddress>P.O. Box 126
Bendigo
Vic 3552</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Studying the Fellow Eye Effect of ranibizumab (Lucentis) injections for macular degeneration.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>9/11/2007</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Jamieson</name>
      <address>144 Arnold St
Bendigo 2550</address>
      <phone>(03) 5441 1622</phone>
      <fax />
      <email>mpjam1@student.monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Jamieson</name>
      <address>144 Arnold St
Bendigo 2550</address>
      <phone>(03) 5441 1622</phone>
      <fax />
      <email>mpjam1@student.monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Jamieson</name>
      <address>144 Arnold St
Bendigo 2550</address>
      <phone>(03) 5441 1622</phone>
      <fax />
      <email>mpjam1@student.monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>